ACET
Overvalued by 29.6% based on the discounted cash flow analysis.
Market cap | $55.42 Million |
---|---|
Enterprise Value | $43.53 Million |
Dividend Yield | $0 (0%) |
Earnings per Share | $-1.33 |
Beta | 1.66 |
Outstanding Shares | 91,071,436 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -0.52 |
---|---|
PEG | -73.59 |
Price to Sales | - |
Price to Book Ratio | 0.63 |
Enterprise Value to Revenue | - |
Enterprise Value to EBIT | -0.34 |
Enterprise Value to Net Income | -1 |
Total Debt to Enterprise | 0.37 |
Debt to Equity | 0.1 |
No data
No data
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell recepto...